The primary endpoint of 12-month Event Free Survival (EFS) for OST-HER2- treated patients (35%) was statistically significant (p= 0.0194) when compared with peer-reviewed comparable historical control ...
Activation of immune blood biomarkers from interferon gamma pathway distinguished long term survivors (>=2 years) from ...
75% of OST-HER2 treated patients achieved 2-year overall survival compared with 40% in the historical control group (p < 0.0001) 100% of patients who achieved 12 month event free survival achieved 2 ...
The firm reported positive results this week from a biomarker analysis in a Phase IIb trial of OST-HER2, which it will submit to regulators.
For children and young adults diagnosed with osteosarcoma, a common type of bone cancer for that age group, the odds of survival can be devastatingly low (20-30%) when the disease spreads to the lungs ...
OS Therapies Inc. (NYSE:OSTX), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, released survival data on Friday from the Phase 2b trial of its off-the-shelf ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback